| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.067 | 0.2 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |